Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: A case report

Journal of Medical Case Reports

Volumn 1, Issue , 2007, Pages

  Takamochi, Kazuya ^a   Suzuki, Kazuya ^a   Bashar, Abul Hasan ^a   Yajima, Kiyoshige ^a   Mochizuki, Takahiro ^a   Itaya, Toru ^a   Funai, Kazuhito ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GENOMIC DNA; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PACLITAXEL; PREDNISOLONE;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECHALLENGE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EXON; FATIGUE; GENE MUTATION; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 45249098533     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-1-138     Document Type: Article

References (15)

1. Ranson M Hammond LA Ferry D Kris M Tullo A Murray PI Miller V Averbuch S Ochs J Morris C ZD a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial J Clin Oncol 1839, 20:2240-50. 10.1200/JCO.2002.10.112
2. Baselga J Rischin D Ranson M Calvert H Raymond E Kieback DG Kaye SB Gianni L Harris A Bjork T Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 1839, 20:4292-302. 10.1200/JCO.2002.03.100
3. Inoue A Saijo Y Maemondo M Gomi K Tokue Y Kimura Y Ebina M Kikuchi T Moriya T Nukiwa T Severe acute interstitial pneumonia and gefitinib Lancet 2003, 361:137-9. 10.1016/S0140-6736(03)12190-3 12531582
4. Ando M Okamoto I Yamamoto N Takeda K Tamura K Seto T Ariyoshi Y Fukuoka M Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 2006, 24:2549-56. 10.1200/JCO.2005.04.9866 16735708
5. Nagai Y Miyazawa H Huqun Tanaka T Udagawa K Kato M Fukuyama S Yokote A Kobayashi K Kanazawa M Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp Cancer Res 2005, 65:7276-82. 10.1158/ 0008-5472.CAN-05-0331 16105816
6. Ho C Davis J Anderson F Bebb G Murray N Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib J Clin Oncol 2005, 23:8531-3. 10.1200/JCO.2004.00.6650 16293881
7. Seki N Uematsu K Shibakuki R Eguchi K Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration J Clin Oncol 2006, 24:3213-4. author reply 3214-5. 10.1200/JCO.2006.05.7109 16809744
8. Yano S Nakataki E Ohtsuka S Inayama M Tomimoto H Edakuni N Kakiuchi S Nishikubo N Muguruma H Sone S Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: A report of three cases Oncol Res 2005, 15:107-11. 16119008
9. Fukuoka M Yano S Giaccone G Tamura T Nakagawa K Douillard JY Nishiwaki Y Vansteenkiste J Kudoh S Rischin D Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 2003, 21:2237-46. 10.1200/JCO.2003.10.038 12748244
10. Kris MG Natale RB Herbst RS Lynch TJ Jr Prager D Belani CP Schiller JH Kelly K Spiridonidis H Sandler A Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial Jama 2003, 290:2149-58. 10.1001/jama.290.16.2149 14570950
11. Mitsudomi T Kosaka T Endoh H Horio Y Hida T Mori S Hatooka S Shinoda M Takahashi T Yatabe Y Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 2005, 23:2513-20. 10.1200/JCO.2005.00.992 15738541
12. Han SW Kim TY Hwang PG Jeong S Kim J Choi IS Oh DY Kim JH Kim DW Chung DH Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 2005, 23:2493-501. 10.1200/JCO.2005.01.388 15710947
13. Lynch TJ Bell DW Sordella R Gurubhagavatula S Okimoto RA Brannigan BW Harris PL Haserlat SM Supko JG Haluska FG Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004, 350:2129-39. 10.1056/NEJMoa040938 15118073
14. Paez JG Janne PA Lee JC Tracy S Greulich H Gabriel S Herman P Kaye FJ Lindeman N Boggon TJ EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 2004, 304:1497-500. 10.1126/science.1099314 15118125
15. Bruce DM Heys SD Eremin O Lymphangitis carcinomatosa: A literature review J R Coll Surg Edinb 1996, 41:7-13. 8930034